Search Results - "Kodumudi, Krithika"

Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy by Pilon-Thomas, Shari, Kodumudi, Krithika N, El-Kenawi, Asmaa E, Russell, Shonagh, Weber, Amy M, Luddy, Kimberly, Damaghi, Mehdi, Wojtkowiak, Jonathan W, Mulé, James J, Ibrahim-Hashim, Arig, Gillies, Robert J

“…Cancer immunotherapies, such as immune checkpoint blockade or adoptive T-cell transfer, can lead to durable responses in the clinic, but response rates remain…”
Get full text

T-cells produce acidic niches in lymph nodes to suppress their own effector functions by Wu, Hao, Estrella, Veronica, Beatty, Matthew, Abrahams, Dominique, El-Kenawi, Asmaa, Russell, Shonagh, Ibrahim-Hashim, Arig, Longo, Dario Livio, Reshetnyak, Yana K., Moshnikova, Anna, Andreev, Oleg A., Luddy, Kimberly, Damaghi, Mehdi, Kodumudi, Krithika, Pillai, Smitha R., Enriquez-Navas, Pedro, Pilon-Thomas, Shari, Swietach, Pawel, Gillies, Robert J.

“…The acidic pH of tumors profoundly inhibits effector functions of activated CD8 + T-cells. We hypothesize that this is a physiological process in immune…”
Get full text

A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers by KODUMUDI, Krithika N, WOAN, Karrune, GILVARY, Danielle L, SAHAKIAN, Eva, SHENG WEI, DJEU, Julie Y

“…Myeloid-derived suppressor cells (MDSC) accumulate in tumor-bearing hosts and are associated with immune suppression. To date, there have only been few studies…”
Get full text

Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy by Basu, Amrita, Ramamoorthi, Ganesan, Albert, Gabriella, Gallen, Corey, Beyer, Amber, Snyder, Colin, Koski, Gary, Disis, Mary L., Czerniecki, Brian J., Kodumudi, Krithika

“…Current success of immunotherapy in cancer has drawn attention to the subsets of T H cells in the tumor which are critical for activation of anti-tumor…”
Get full text

Immune Checkpoint Blockade to Improve Tumor Infiltrating Lymphocytes for Adoptive Cell Therapy by Kodumudi, Krithika N, Siegel, Jessica, Weber, Amy M, Scott, Ellen, Sarnaik, Amod A, Pilon-Thomas, Shari

“…Tumor-infiltrating lymphocytes (TIL) has been associated with improved survival in cancer patients. Within the tumor microenvironment, regulatory cells and…”
Get full text

Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma by Kodumudi, Krithika N, Weber, Amy, Sarnaik, Amod A, Pilon-Thomas, Shari

“…Administration of nonmyeloablative chemotherapeutic agents or total body irradiation (TBI) prior to adoptive transfer of tumor-specific T cells may reduce or…”
Get full text

Immunotherapy in breast cancer: Current status and future directions by Basu, Amrita, Ramamoorthi, Ganesan, Jia, Yongsheng, Faughn, Jon, Wiener, Doris, Awshah, Sabrina, Kodumudi, Krithika, Czerniecki, Brian J

“…Breast cancer, one of the leading causes of death in women in the United States, challenges therapeutic success in patients due to tumor heterogeneity,…”
Get full text

Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway by Jia, Yongsheng, Kodumudi, Krithika N., Ramamoorthi, Ganesan, Basu, Amrita, Snyder, Colin, Wiener, Doris, Pilon-Thomas, Shari, Grover, Payal, Zhang, Hongtao, Greene, Mark I., Mo, Qianxing, Tong, Zhongsheng, Chen, Yong-Zi, Costa, Ricardo L.B., Han, Hyo, Lee, Catherine, Soliman, Hatem, Conejo-Garcia, Jose R., Koski, Gary, Czerniecki, Brian J.

“…HER2 breast cancer (BC) remains a significant problem in patients with locally advanced or metastatic BC. We investigated the relationship between T helper 1…”
Get full text

Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response by Kodumudi, Krithika N, Ramamoorthi, Ganesan, Snyder, Colin, Basu, Amrita, Jia, Yongsheng, Awshah, Sabrina, Beyer, Amber P, Wiener, Doris, Lam, Lian, Zhang, Hongtao, Greene, Mark I, Costa, Ricardo L B, Czerniecki, Brian J

“…Patients with metastatic HER2 breast cancer (MBC) often become resistant to HER 2 targeted therapy and have recurrence of disease. The Panacea trial suggested…”
Get full text

Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination by Zachariah, Nadia Nocera, Basu, Amrita, Gautam, Namrata, Ramamoorthi, Ganesan, Kodumudi, Krithika N, Kumar, Nagi B, Loftus, Loretta, Czerniecki, Brian J

“…Breast cancer (BC) prevention remains the ultimate cost-effective method to reduce the global burden of invasive breast cancer (IBC). To date, surgery and…”
Get full text

T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model by Liu, Hao, Weber, Amy, Morse, Jennifer, Kodumudi, Krithika, Scott, Ellen, Mullinax, John, Sarnaik, Amod A, Pilon-Thomas, Shari

“…Intralesional (IL) injection of Rose Bengal (PV-10) induces regression of injected and uninjected lesions in several murine tumor models. In this study, we…”
Get full text

Icariin and its derivative, ICT, exert anti-inflammatory, anti-tumor effects, and modulate myeloid derived suppressive cells (MDSCs) functions by Zhou, Junmin, Wu, Jinfeng, Chen, Xianghong, Fortenbery, Nicole, Eksioglu, Erika, Kodumudi, Krithika N., PK, Epling-Burnette, Dong, Jingcheng, Djeu, Julie Y., Wei, Sheng

“…3, 5, 7-Trihydroxy-4′-methoxy-8-(3-hydroxy-3-methylbutyl)-flavone (ICT) is a novel derivative of Icariin (ICA), the major active ingredient of Herba Epimedii,…”
Get full text

Anti-tumor efficacy of plasmid encoding emm55 in a murine melanoma model by Bunch, Brittany L., Kodumudi, Krithika N., Scott, Ellen, Morse, Jennifer, Weber, Amy Mackay, Berglund, Anders E., Pilon-Thomas, Shari, Markowitz, Joseph

“…Emm55 is a bacterial gene derived from Streptococcus pyogenes ( S. pyogenes ) that was cloned into a plasmid DNA vaccine (pAc/emm55). In this study, we…”
Get full text

Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer by Toomey, Paul, Kodumudi, Krithika, Weber, Amy, Kuhn, Lisa, Moore, Ellen, Sarnaik, Amod A, Pilon-Thomas, Shari

“…Intralesional (IL) injection of PV-10 has shown to induce regression of both injected and non-injected lesions in patients with melanoma. To determine an…”
Get full text

MP48-20 EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES (TIL) FROM PRIMARY BLADDER TUMORS by Poch, Michael, Hall, Maclean, Kodumudi, Krithika Kodumudi, Croft, Cortlin, Fishman, Mayer, Mullinax, John, Sarniak, Amod, Mule, James, Pilon-Thomas, Shari

Get full text

Abstract 2292: Reconstitution of myeloid derived suppressor cells after the induction of lymphopenia and TIL therapy by Kodumudi, Krithika N., Wiener, Doris, Weber, Amy, Royster, Erica, Kelley, Linda, Sarnaik, Amod, Pilon-Thomas, Shari

“…Abstract Factors such as T regulatory (Treg) cells and myeloid derived suppressor cells (MDSC) limit the effectiveness of current immunotherapy protocols…”
Get full text

Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma by Kodumudi, Krithika N, Weber, Amy, Sarnaik, Amod A, Pilon-Thomas, Shari

Get full text

Differential expression of TLR-2 and TLR-4 in the epithelial cells in oral lichen planus by Janardhanam, Srihari B, Prakasam, Sivaraman, Swaminathan, Venkatesh T, Kodumudi, Krithika N, Zunt, Susan L, Srinivasan, Mythily

“…Abstract Objective Oral lichen planus (OLP) is a chronic inflammatory condition of the mucosa mediated by a complex signalling network between the…”
Get full text

Abstract 4978: T cell mediated immunity after combination therapy with intralesional PV-10 and co-inhibitory blockade in a melanoma model by Weber, Amy M., Liu, Hao, Kodumudi, Krithika N., Sarnaik, Amod A., Pilon-Thomas, Shari

“…Abstract PV-10 is a 10% solution of Rose Bengal, a xanthene dye that was originally developed for ophthalmic use and later used in liver function studies…”
Get full text

Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4 + Th1 Responses and Potential Use as a Cancer Vaccine by Basu, Amrita, Albert, Gabriella K, Awshah, Sabrina, Datta, Jashodeep, Kodumudi, Krithika N, Gallen, Corey, Beyer, Amber, Smalley, Keiran S M, Rodriguez, Paulo C, Duckett, Derek R, Forsyth, Peter A, Soyano, Aixa, Koski, Gary K, Lima Barros Costa, Ricardo, Han, Heather, Soliman, Hatem, Lee, Marie Catherine, Kalinski, Pawel, Czerniecki, Brian J

“…The HER3/ERBB3 receptor is an oncogenic receptor tyrosine kinase that forms heterodimers with EGFR family members and is overexpressed in numerous cancers…”
Get more information